U.S. Markets close in 5 hrs 20 mins

Champions Oncology (CSBR) Gains As Market Dips: What You Should Know

Zacks Equity Research
NantHealth, Inc. (NH) delivered earnings and revenue surprises of 23.08% and -10.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

In the latest trading session, Champions Oncology (CSBR) closed at $12.21, marking a +0.58% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.55%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.42%.

Heading into today, shares of the company had lost 10.34% over the past month, lagging the Medical sector's loss of 6.09% and the S&P 500's loss of 5.71% in that time.

Investors will be hoping for strength from CSBR as it approaches its next earnings release, which is expected to be December 6, 2018. Our most recent consensus estimate is calling for quarterly revenue of $6.35 million, up 22.12% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $0.17 per share and revenue of $25.31 million, which would represent changes of +440% and +25.06%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for CSBR. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CSBR is holding a Zacks Rank of #1 (Strong Buy) right now.

Valuation is also important, so investors should note that CSBR has a Forward P/E ratio of 71.41 right now. Its industry sports an average Forward P/E of 16.87, so we one might conclude that CSBR is trading at a premium comparatively.

The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 38% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow CSBR in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Champions Oncology, Inc. (CSBR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.